Saliva Quantification of SARS-CoV-2 in Real-Time PCR From Asymptomatic or Mild COVID-19 Adults

Florence Carrouel1,*, Emilie Gadea2,3, Aurélie Esparcieux4, Jérome Dimet5, Marie Elodie Langlois6, Hervé Perrier7, Claude Dussart1 and Denis Bourgeois1

1 Health, Systemic, Process, UR4129 Research Unit, University Claude Bernard Lyon 1, University of Lyon, Lyon, France, 2 Equipe SNA-EPIS, EA4607, University Jean Monnet, Saint-Etienne, France, 3 Clinical Research Unit, Erme Roux Hospital Center, Le Puy-en-Velay, France, 4 Department of Internal Medicine and Infectious Diseases, Protestant Infirmary, Caluire-et-Cuire, France, 5 Clinical Research Center; Intercommunal Hospital Center of Mont de Marsan et du Pays des Sources, Mont de Marsan, France, 6 Department of Internal Medicine and Infectious Diseases, Saint Joseph Saint Luc Hospital, Lyon, France, *Clinical Research Unit, Protestant Infirmary, Lyon, France

The fast spread of COVID-19 is related to the highly infectious nature of SARS-CoV-2. The disease is suggested to be transmitted through saliva droplets and nasal discharge. The saliva quantification of SARS-CoV-2 in real-time PCR from asymptomatic or mild COVID-19 adults has not been fully documented. This study analyzed the relationship between salivary viral load on demographics and clinical characteristics including symptoms, co-morbidities in 160 adults diagnosed as COVID-19 positive patients recruited between September and December 2020 in four French centers. Median initial viral load was 4.12 log_{10} copies/mL (IQR 2.95–5.16; range 0–10.19 log_{10} copies/mL). 68.6% of adults had no viral load detected. A median load reduction of 23% was observed between 0–2 days and 3–5 days, and of 11% between 3–5 days and 6–9 days for the delay from onset of symptoms to saliva sampling. No significant median difference between no-symptoms vs. symptoms patients was observed. Charge was consistently similar for the majority of the clinical symptoms excepted for headache with a median load value of 3.78 log_{10} copies/mL [1.95–4.58] (P < 0.003). SARS-CoV-2 RNA viral load was associated with headache and gastrointestinal symptoms. The study found no statistically significant difference in viral loads between age groups, sex, or presence de co-morbidity. Our data suggest that oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission.

Keywords: SARS-CoV-2, COVID-19, saliva, viral load, virus isolation, real-time reverse transcription PCR, infectivity, quantitative

INTRODUCTION

The fast spread of COVID-19 is related to the highly infectious nature of SARS-CoV-2. The disease is suggested to be transmitted through saliva droplets and nasal discharge (Li Y. et al., 2020). Indeed, SARS-CoV-2 is found in nasopharyngeal secretions, and its viral load is consistently high in the saliva, mainly in the early stage of the disease (Sapkota et al., 2020). In addition to saliva secreted...
by the major or minor salivary glands, saliva samples also contain secretions from the nasopharynx or from the lungs through the action of cilia lining the airway (Huang et al., 2021). Saliva can have potential applications in the context of COVID-19 by direct detection of the virus, quantification of the specific immunoglobulins produced against it, and for the evaluation of the non-specific, innate immune response of the patient (Ceron et al., 2020). Up to date, several cross-sectional and clinical trial studies published support the potential of detecting SARS-CoV-2 RNA in saliva as a biomarker for COVID-19, providing a self-collection, non-invasive, safe, and comfortable procedure (Caixeta et al., 2021; Carrouel et al., 2021).

Most published RT-qPCR assays for the diagnosis of SARS-CoV-2 are qualitative (Han et al., 2021). Considering the variability of viral load between and within patients, quantification of absolute viral load directly from pure raw saliva is important for COVID-19 diagnosis and monitoring (Vasudevan et al., 2021). Quantification of viral load has other objectives compared to screening. It gives an indication of the degree of contagiousness, provides guidance on the interest to predict contagiousness of patients and hence to guide epidemiological decisions, to evaluate different samples from different anatomical locations, to predict the patient prognosis and assess disease progression (Jacot et al., 2020). In this context, evidence reports on the salivary viral load or duration of viral detection or infectivity of COVID-19 to trace the disease and to implement strategies aimed at breaking the chain of disease transmission are particularly important (Huang et al., 2021). Overall, the studies were of low-to-moderate quality given that most of the included studies comprised case series and case reports at the early stages of the pandemic (Nasserie et al., 2021). Furthermore, given the number of studies analyzing the Chinese population, it is quite possible that the results cannot be generalized to other populations, especially to asymptomatic cases linked to 80% of disease transmission (Walsh et al., 2020). There is consensus that these results should be viewed with caution and should be confirmed by larger, more robust studies. It is clear that more research is needed on this topic to correlate viral load with symptoms and clinical outcomes (Mahallawi et al., 2021).

Hart et al. (2021) showed that about 65% of virus transmission occurs before symptoms develop. Thus, individuals circulate in the general community before their infections are detected (Hart et al., 2021). To better understand SARS-CoV-2 infectiousness before symptoms develop or with mild symptoms, we analyzed salivary viral load at the moment of disease. The purpose of this study is to outline the salivary SARS-CoV-2 viral load over the course of the infection in asymptomatic or mild COVID-19 adults.

**MATERIALS AND METHODS**

**Study Design and Subjects**

This analysis was a part of the randomized controlled trial BBCovid protocol published (Carrouel et al., 2020) and registered at ClinicalTrials.gov (NCT04352959). One hundred and sixty subjects diagnosed as COVID-19 positive patient were recruited between September and December 2020 in four French hospital centers. The study protocol was reviewed and approved by the National Ethics Committee “Committee for the Protection of Persons South Mediterranean III,” France (2020.04.11 sept _20.04.06.46640). Written informed consent was obtained from all enrolled individuals. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization–Good Clinical Practice guidelines.

The inclusion criteria were: (i) age 18–85 years-old, (ii) RT-PCR positive COVID-19 nasopharyngeal swab, (iii) asymptomatic or mild clinical symptoms for less than 8 days.

The exclusion criteria were: (i) pregnancy, (ii) breastfeeding, (iii) risk of infectious endocarditis, (iii) use of mouthwash regularly (more than once a week), (iv) inability to comply with protocol, (v) lack of written agreement, (vi) unable to answer questions, and (vii) uncooperative patients.

**Collecting of Demographic Data and Clinical Characteristics of Subjects**

During the inclusion visit, demographic data (age, sex) and clinical characteristics (co-morbidities, symptoms, date of apparition of symptoms…) were collected from the subjects. Reporting of the nature of the symptoms was recorded at the time of the viral load measurement. An electronic medical record (e-CRF) permitted to record all these informations.

**Quantification of SARS-CoV-2 Salivary Load**

**Saliva Sampling**

At 9 a.m., each subject collected one salivary sample with an accredited health care professional using the Saliva Collection System kit (Greiner Bio-one, Kremmen, Austria). Only one sample was collected from each adult. Firstly, with the saliva extraction solution, the subject rinsed the oral cavity for 2 min. Secondly, the subject spit into a saliva-collection beaker, without coughing or scraping to clear the throat, to collect the non-stimulated and pure saliva (between 1 and 3.5 mL). Finally, the saliva sample transferred to a sterile tube and stored at 4°C until analysis.

**Quantification of SARS-CoV-2 Viral Load by Real-Time RT-PCR**

RNA was extracted from 200 µL of saliva sample using the NucliSens easyMAG instrument (bioMérieux, Marcy-l’Etoile, France), according to the manufacturer’s guidelines. The RNA was eluted in 50 µL of water and used as a template for real-time (rt) RT-PCR.

Real-time RT-PCR assays were performed with the Invitrogen Superscript® III Platinum One-Step qRT-PCR system (Invitrogen, Illkirch, France). The mix was composed of 5 µL of extracted RNA, 1 µL of Superscript III RT/Platinum Taq Mix, 12.5 µL of 2X reaction buffer, 0.4 µL of a 50 mM magnesium sulfate solution, 1 µL of RdRp-IP2 forward primer (0.4 µM), 1 µL of RdRp-IP2 reverse primer (0.4 µM), 1 µL of...
RdRp-IP4 forward primer (0.4 μM), 1 μL of RdRp-IP4 reverse primer (0.4 μM). The primer and probe sequences correspond to the RdRp-IP2 and the RdRp-IP4 assays designed at The Institut Pasteur to target a section of the RdRp gene (nt 12621-12727 and 14010-14116 positions) based on the sequences of SARS-CoV-2 (NC_004718) made available on the Global Initiative on Sharing All Influenza Data database on 11 January 2020 (Table 1). These primers and probes were manufactured by Eurofins (Genomics, Germany).

The assays were performed on a Quant Studio 5 (Thermo Fisher Scientific, Dardilly, France) with the following program: 55°C for 10 min (reverse transcription), followed by 95°C for 2 min, and then 45 cycles of 95°C for 3 s and 58°C for 30 s. Each run included three negatives’ samples bracketing unknown samples during RNA extraction, two positive controls, and one negative amplification control. When a sample was positive for RdRp-IP4, the quantification of the number of RNA copies was performed according to a scale ranging from 10^2 to 10^6 copies per μL. The SARS-CoV-2 viral load in saliva was calculated as the number of RNA copies per mL of saliva.

**Statistical Analysis**

SPSS Windows 20.0 (IBM, Chicago, IL, United States) was used for the descriptive statistics median and interquartile range (IQR) and mean values with SD for the quantitative variables and percentages for categorical variables. One-way ANOVA was used to compare the differences of median between groups in a univariate analysis. Binary logistic regression analysis was used to model the relationship between viral load values as the dependent variable and the other parameters were entered individually as independent variables (adjusted for age and gender). The detailed statistical methods are indicated in the table footnotes. All data were considered statistically significant when p < 0.05.

**RESULTS**

**Demographic Data and Clinical Characteristics of Subjects**

The sex, the age and the clinical assessments of the study group are summarized in Table 2. The sample consisted of 160 subjects (55.97% of females and 44.03% of males) with a mean age of 43.62 ± 15.56 years. One co-morbidity was declared by 22.15% of subjects. The median time between symptoms onset and the positive nasopharyngeal RT-PCR was 4 days [IQR 3–5]. The median number of symptoms per subjects was 4 [IQR 2–5]. The most frequent symptoms described by 52.87% of subjects were the cough and the headache followed by myalgia in 48.41% of subjects. Fever was reported in 41.40% of subjects; anosmia in 40.13% of subjects; ageusia in 38.22% of subjects; dyspnea in 12.74% of subjects and; gastrointestinal symptoms in 8.92% of subjects. The absence of symptoms was only observed in 8.92% of subjects. For symptomatic subjects, the saliva sample was collected in median 6 days [IQR 5–7] after the onset of symptoms.

**Quantification of SARS-CoV-2 Viral Load According to Demographics and Clinical Characteristics of Participants**

Median initial viral load was 4.12 log_{10} copies/mL (IQR 2.95–5.16 log_{10} copies/mL, range 0–10.19 log_{10} copies/mL). The first quartile (Q1) corresponded to a viral load starting at 2.95 log_{10} copies/mL, whereas the second (Q2) corresponded to a viral load starting at 4.12 log_{10} copies/mL, and the third (Q3) corresponded to a viral load starting at 5.16 log_{10} copies/mL.

The SARS-CoV-2 salivary viral load according to demographics and clinical characteristics of participants are described in Table 3 and Figures 1, 2. The median SARS-CoV-2 salivary viral load increased not significantly with age groups from 3.82 log_{10} copies/mL (18–34 years) to 4.31 log_{10} copies/mL (55–77 years). Salivary viral load was not associated with sex. The presence of co-morbidity or not, did not significantly modify the SARS-CoV-2 salivary viral load. Same observation was done for the time between RT-PCR and symptom onset, the delay from symptom onset to saliva sampling and for the number of symptoms per participants. Patients with symptoms demonstrated a median initial viral load of 4.12 log_{10} copies/mL (IQR 2.95–5.16; range 0–10.19 log_{10} copies/mL), while the no-symptoms patients had indices of 4.01 log_{10} copies/mL (IQR 0.56–5.75 log_{10} copies/mL), range 0–6.24 log_{10} copies/mL).

**Determination of Factors Associated With SARS-CoV-2 Salivary Viral Load**

The analysis of the mean difference of SARS-CoV-2 salivary load was reported in Table 4. For the delay from onset of symptoms

---

**Table 1 | RT-PCR for the detection of SARS-CoV-2: primers and probes used.**

| Name            | Sequences (5′–3′)                  | PCR product | References |
|-----------------|------------------------------------|-------------|------------|
| **RdRp gene/nCoV_IP2** |                                     |             |            |
| nCoV_IP2-12669Fw | ATGAGCCTTAGTCCCTGTGTG           | 108 pb      | CNR*       |
| nCoV_IP2-12759Rv | CTCCCTTGTGGTGTGTG            |             | CNR*       |
| nCoV_IP2-12669bProbe(+) | [5′]HEX-AGATGTCTTTGTGCTGCGGTA-[3′]BHQ-1 |             | CNR*       |
| **RdRp gene/nCoV_IP4** |                                     |             |            |
| nCoV_IP4-14059Fw | GGTAACCTGGATGATTTCG          | 107 pb      | CNR*       |
| nCoV_IP4-14146Rv | CTGCTGCAAGTTAATAGG          |             | CNR*       |
| nCoV_IP4-14084Probe(+) | [5′]Fam−TCATACAAACCACGCCAGG−[3′]BHQ-1 |             | CNR*       |

*CNR: National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.*
TABLE 2 | Baseline characteristics of enrolled patients with Coronavirus Disease 2019.

| Variable | Gender, n/N* (%) | Age (years) | Age (class), n/N* (%) | Co-morbidity, n/N* (%) | Time between positive RT-PCR and symptom onset (days) | Number of symptoms per subjects, n/N* (%) | Symptoms, n/N* (%) | Delay from symptom onset to saliva sampling (days) |
|----------|------------------|-------------|-----------------------|------------------------|-----------------------------------------------|-------------------------------------------|-------------------|-----------------------------------------------|
|          | Male 70/159 (44.03%) | N = 158 | Mean ± SD: 43.62 ± 15.56 | 18–34 years 52/158 (32.91%) | Mean ± SD: 3.93 ± 1.46 | Mean ± SD: 3.71 ± 2.27 | None 14/157 (8.92%) | N = 141 |
|          | Female 89/159 (55.97%) | Median [IQR]: 43 [30–65] | Median [IQR]: 43 [30–65] | 35–54 years 65/158 (41.14%) | Median [IQR]: 41 [30–65] | Median [IQR]: 41 [30–65] | 1–4 40/157 (25.48%) | Mean ± SD: 5.55 ± 1.62 |
|          |                  | Age (class), n/N* (%) | 55–77 years 41/158 (25.95%) | Co-morbidity, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) | Number of symptoms per subjects (class), n/N* (%) | Symptoms, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) |
|          |                  | Mean ± SD: 43.62 ± 15.56 | Mean ± SD: 43.62 ± 15.56 | Co-morbidity, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) | Number of symptoms per subjects (class), n/N* (%) | Symptoms, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) |
|          |                  | Median [IQR]: 43 [30–65] | Median [IQR]: 43 [30–65] | Co-morbidity, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) | Number of symptoms per subjects (class), n/N* (%) | Symptoms, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) |
|          |                  | Mean ± SD: 43.62 ± 15.56 | Mean ± SD: 43.62 ± 15.56 | Co-morbidity, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) | Number of symptoms per subjects (class), n/N* (%) | Symptoms, n/N* (%) | Delay from symptom onset to saliva sampling (class), n/N* (%) |

n, Number of subjects. N, Total number of subjects.
*N/N, Number of subjects/Total number of subjects.

To saliva sampling, the SARS-CoV-2 salivary load continuously decreased with the of the days. A median load reduction of 23% was observed between 0–2 days and 3–5 days, and of 11% between 3–5 days and 6–9 days. However, no significant difference between the groups was detected.

TABLE 3 | Association of viral Load with demographics and clinical parameters for all enrolled participants: N: number of subjects.

| Variable | N | Viral load, median [95% CI] | p-value |
|----------|---|-----------------------------|---------|
| Sex      |   |                             | 0.290^a |
| Male     | 70 | 4.48 [2.99–5.54]            |         |
| Female   | 89 | 4.02 [2.18–4.69]            |         |
| Age      |   |                             | 0.290^b |
| 18–34 years | 52 | 3.82 [2.89–4.57]            |         |
| 35–54 years | 65 | 4.14 [2.72–5.72]            |         |
| 55–77 years | 41 | 4.31 [2.94–5.62]            |         |
| Co-morbidity |   |                             | 0.856^a |
| No       | 116 | 4.12 [2.95–5.15]            |         |
| Yes      | 33  | 4.12 [3.01–5.5]             |         |
| Time between positive RT-PCR and symptom onset |   |                             | 0.637^b |
| 0–2 days | 27  | 4.33 [2.62–5.09]            |         |
| 3–5 days | 108 | 4.13 [2.94–5.48]            |         |
| 6–8 days | 18  | 4.08 [2.81–4.82]            |         |
| Delay from symptom onset to saliva sampling |   |                             | 0.206^c |
| 0–2 days | 7   | 5.63 [3.91–5.88]            |         |
| 3–5 days | 57  | 4.34 [2.75–5.47]            |         |
| 6–9 days | 77  | 3.86 [2.96–4.72]            |         |
| Number of symptoms per subjects |   |                             | 0.573^b |
| None     | 14  | 4.01 [0.56–5.75]            |         |
| 1–4      | 40  | 3.85 [2.16–4.75]            |         |
| 5–6      | 65  | 4.29 [3.4–5.49]             |         |
| 7–9      | 38  | 3.93 [2.98–5.16]            | 0.004^a |
| Fever    |   |                             |         |
| No       | 92  | 4.07 [2.6–5.01]             |         |
| Yes      | 65  | 4.24 [3.04–5.47]            | 0.097^a |
| Cough    |   |                             |         |
| No       | 74  | 3.83 [2.05–4.74]            |         |
| Yes      | 83  | 4.14 [3.03–5.48]            |         |
| Dyspnea  |   |                             |         |
| No       | 137 | 4.12 [2.75–5.17]            |         |
| Yes      | 20  | 4.13 [2.77–5.04]            |         |
| Headache |   |                             |         |
| No       | 74  | 3.78 [1.95–4.58]            | 0.721^a |
| Yes      | 83  | 4.51 [3.32–5.59]            |         |
| Myalgia  |   |                             |         |
| No       | 81  | 4.14 [2.25–5.02]            | 0.126^a |
| Yes      | 76  | 4.10 [2.98–5.29]            |         |
| Gastrointestinal symptoms |   |                             |         |
| No       | 143 | 4.12 [2.95–5.17]            | 0.147^a |
| Yes      | 14  | 3.88 [0.4–5.47]             |         |
| Anosmia  |   |                             |         |
| No       | 94  | 4.29 [2.95–5.5]             |         |
| Yes      | 63  | 3.78 [2.7–4.54]             | 0.212^a |
| Ageusia  |   |                             |         |
| No       | 97  | 4.26 [2.94–5.49]            |         |
| Yes      | 60  | 3.78 [2.71–4.59]            |         |

^aMann-Whitney test.
^bKruskal-Wallis test.
^cANOVA test.
Concerning the time between positive RT-PCR and symptom onset, a non-significant decrease of $-0.12 \log_{10} \text{copies/mL} \ [\text{IQR} -0.34–0.10]$ was observed. First, an increase $0.26 \log_{10} \text{copies/mL} \ [\text{IQR} -0.67–1.18]$ was observed at 3–5 days compared with 0–2 days. Then, a decrease of $-0.39 \log_{10} \text{copies/mL} \ [\text{IQR} -1.70–0.92]$ was observed at 6–8 days.

Between no-symptoms patients with an initially salivary SARS-CoV-2 load of $4.01 \log_{10} \text{copies/mL} \ [\text{IQR} 0.56–5.75]$ and patients with symptoms (Table 3), there was no significant median difference in the viral load (Table 4). However, COVID-19 adults declaring 5–6 or 7–9 symptoms have a higher viral median difference charge of $0.56 \log_{10} \text{copies/mL} \ [\text{IQR} -0.71–1.83]$ and $0.50 \log_{10} \text{copies/mL} \ [\text{IQR} -0.85–1.85]$ respectively.

The salivary SARS-CoV-2 viral load was consistently similar for the majority of the clinical symptoms concerned even if SARS-CoV-2 salivary load increased in presence of fever $0.24 \log_{10} \text{copies/mL} \ [\text{IQR} -0.46–0.93]$, cough $0.58 \log_{10} \text{copies/mL} \ [\text{IQR} -0.10–1.26]$, dyspnea $0.50 \log_{10} \text{copies/mL} \ [\text{IQR} -0.53–1.53]$ and myalgia $0.19 \log_{10} \text{copies/mL} \ [\text{IQR} -0.50–0.88]$. With a median difference increase of $1.04 \log_{10} \text{copies/mL} \ [\text{IQR} 0.37–1.71]$, headache in confirmation of symptomatic cases influence significantly the salivary viral load ($P < 0.003$) (Table 4). The patients without headache had a mean salivary viral load of $3.78 \log_{10} \text{copies/mL} \ [\text{IQR} 1.95–4.58]$ whereas patients with headache had a mean salivary viral load of $4.51 \log_{10} \text{copies/mL} \ [\text{IQR} 3.32–5.59]$ (Table 3).
In multivariate logistic regression analysis, the relation between salivary viral load and headache and GI symptoms remained significant after adjustment for age and sex ($P = 0.004$ and $P = 0.043$, respectively) (Table 5).

DISCUSSION

The present study was designed to explore the quantification of SARS-CoV-2 in pure saliva of adults with asymptomatic to mild COVID-19. This robust multicenter observational trial, including 160 individuals, is the first, to our knowledge, to target this specific population—mean age of patients was $43.62 \pm 15.56$ years- and to describe the sociodemographic and clinical characteristics of the salivary viral load. The load SARS-CoV-2 value of the whole sample ranged from 0.00 to 10.19 with a median of $4.12 \log_{10}$ copies/mL (IQR $2.95–5.16 \log_{10}$ copies/mL), 27/159 patients (16.98%) had no charge. Between no-symptoms patients with an initially salivary SARS and patients with symptoms, there was no significant

![Figure 2](https://www.frontiersin.org/article/10.3389/fmicb.2021.786042)
TABLE 4 | Association of viral load with sex, age, symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: univariable analysis.

| Variable                                      | References level | Class level | Mean difference [95% CI] | p-value |
|-----------------------------------------------|------------------|-------------|--------------------------|---------|
| Age                                           | CV               | 0.02        | [−0.01–0.04]             | 0.179   |
| Age (class)                                   |                  | 18–34       | 0.40                     | [−0.40–1.20] | 0.330   |
|                                              |                  | 35–54       | 0.42                     | [−0.48–1.32] | 0.359   |
|                                              |                  | 55–77       | 0.42                     | [−0.28–1.16] | 0.359   |
| Gender                                        | Male             | Female      | −0.60                    | [−1.28–0.08] | 0.084   |
| Co-morbidity                                  | No               | Yes         | −0.01                    | [−0.83–0.81] | 0.974   |
| Time between positive RT-PCR and symptom onset| CV               | −0.11       | [−0.35–0.13]             | 0.354   |
| Time between positive RT-PCR and symptom onset (class)| 0–2 days | 3–5 days | 0.26                     | [−0.67–1.16] | 0.583   |
|                                              |                  | 6–8 days    | −0.39                    | [−1.70–0.92] | 0.350   |
| Delay from symptom onset to saliva sampling   | CV               | −0.12       | [−0.34–0.10]             | 0.283   |
| Delay from symptom onset to saliva sampling (class)| 0–2 days | 3–5 days | −0.87                    | [−2.55–0.81] | 0.312   |
|                                              |                  | 6–9 days    | −1.31                    | [−2.96–0.35] | 0.124   |
| Number of symptoms per subjects              | CV               | 0.08        | [−0.07–0.24]             | 0.275   |
| Number of symptoms per subjects (class)      | None             | 1–4         | 0.02                     | [−1.31–1.36] | 0.973   |
|                                              |                  | 5–6         | 0.56                     | [−0.71–1.83] | 0.387   |
|                                              |                  | 7–9         | 0.50                     | [−0.85–1.85] | 0.468   |
| Symptoms                                      | None             | Yes         | No                       | −0.39 | [−1.60–0.81] | 0.522   |
|                                              | Fever            | No          | Yes                      | 0.24  | [−0.46–0.93] | 0.504   |
|                                              | Cough            | No          | Yes                      | 0.58  | [−0.10–1.26] | 0.097   |
|                                              | Dyspnea          | No          | Yes                      | 0.50  | [−0.53–1.53] | 0.341   |
|                                              | Headache         | No          | Yes                      | 1.04  | [0.37–1.71]  | 0.003   |
|                                              | Myalgia          | No          | Yes                      | 0.19  | [−0.50–0.88] | 0.589   |
|                                              | Grasto-intestinal symptoms | No | Yes | −0.98 | [−2.17–0.22] | 0.112   |
|                                              | Anosmia          | No          | Yes                      | −0.29 | [−0.99–0.41] | 0.423   |
|                                              | Ageusia          | No          | Yes                      | −0.25 | [−0.95–0.46] | 0.497   |

CV: continuous variable.

TABLE 5 | Association of viral load with sex, age, symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: Multivariable Analysis.

| Variable                                      | References level | Class level | Mean difference [95% CI] | p-value |
|-----------------------------------------------|------------------|-------------|--------------------------|---------|
| Age                                           | CV               | 0.01        | [−0.01–0.04]             | 0.188   |
| Gender                                        | Male             | Female      | −0.56                    | [−1.23–0.11] | 0.102   |
| Cough                                         | No               | Yes         | 0.40                     | [−0.28–1.08] | 0.250   |
| Headache                                      | No               | Yes         | 1.02                     | [0.34–1.7]  | 0.004   |
| Grasto-intestinal symptoms                    | No               | Yes         | −1.22                    | [−2.39–0.06] | 0.043   |

CV, continuous variable.

median difference in the viral load. Collectively, these data show that the oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission.

While self-collected saliva is a realistic alternative option for the diagnosis of COVID-19, there are no significant studies in the literature evaluating the salivary viral load of adults with asymptomatic, to mild COVID-19. If Huang et al. (2021) suggest two possible sources for SARS-CoV-2 in saliva: an acellular fraction from infected glands making virus de novo and a cellular fraction from infected and shed oral mucosa, little is known about the correlation between viral load and age, gender, symptoms, and comorbidity. The first study quantifying the salivary load of SARS-CoV-2 included 12 hospitalized patients with laboratory-confirmed COVID-19, with a median age of 62.5 years. SARS-CoV-2 was detected in 91.7% of throat saliva samples from COVID-19 patients, and the number was as high as $1 \times 10^8$ infectious copies per milliliter (To et al., 2020). Observational studies are subject to a number of different biases (Accorsi et al., 2021). Lecture of meta-analysis of diagnostic results from saliva (Moreira et al., 2021) reveals that no studies met our objective and methodological criteria.

So, studies included different subgroups categorized by gradation of disease severity, primarily in patients who developed severe disease admitted to intensive care during their hospital stay, and both inpatients with moderate disease symptoms (Alteri et al., 2020; Jeong et al., 2020; Kam et al., 2020; Kim et al., 2020; Lai et al., 2020; Pan et al., 2020; Pujadas et al., 2020; To et al., 2020; Yoon et al., 2020; Yu et al., 2020; Abasiyanik et al., 2021; Chua et al., 2021; Han et al., 2021;
Hasanoglu et al., 2021). Then, participants were included with a diverse range of COVID-19 disease severity, including in majority cases hospitalized, and individuals with resolved infection. So, different diagnosis methods were used in self-collected saliva as nucleic acid amplification testing, transcription mediated amplification, reverse transcription loop-mediated isothermal amplification, TRIzol-based RNA extraction, despite quantitative reverse transcription PCR is the diagnostic standard for SARS-CoV-2 (Nagura-Ikeda et al., 2020). Several papers used the naive Ct values from qualitative RT-PCR as a quantitation for SARS-CoV-2 (Nagura-Ikeda et al., 2020). Several papers used the naive Ct values from qualitative RT-PCR as a quantitation unit or use the ΔCt values with incorrect quantitation unit (Shen et al., 2020; Zou et al., 2020). Saliva collection protocols for included studies were assessed for differences with respect to asking patients to collect pure saliva or to cough or clear their throat before submission of enhanced sample likely mixed sputum and saliva specimen or deep throat saliva specimen or requesting the patients submit “drool” or “spit” (Carrouel et al., 2020; Khiabani and Amirzade-Iran, 2021).

With reference to viral load during infection in asymptomatic or mildly affected adults with COVID-19, we observed that viral load is generally high, although asymptomatic viral loads are not statistically different from symptomatic viral loads, tending, however, to be lower. These results highlight the potential infectivity of saliva although the possible threshold of transmissibility is not specified and there is no standard reference in this regard. In particular, these results suggest that expelled oral droplets containing infectious virus and infected cells may be a source of airborne transmission of SARS-CoV-2. SARS-CoV-2 transmission from people who are either asymptomatic or mild has implications for prevention. Social distancing measures will need to be sustained at some level because droplet transmission from close contact with people with asymptomatic and mild infection occurs (Bazant and Bush, 2021). Easing of restrictions will, however, only be possible with wide access to testing, contact tracing, and rapid isolation of infected individuals.

The mean age of patients in our study was 43.6 years. We found that gender and age are not factors affecting viral load. According to published data, younger patients would be more likely to be asymptomatic than older patients (Li Y. et al., 2020). Studies have shown that both older age and male gender are associated with severe disease (Qian et al., 2020). To et al. (2020) found similar results to Zheng et al. (2020) and both concluded that older age is associated with higher viral load. Mahallawi et al. (2021) studied the viral load of lower and upper respiratory tract specimens from 3,006 COVID-19 positive patients. They found no statistically significant difference between age groups, while the viral load was statistically significantly higher in women than in men.

Specific observational studies as well as modeling work have shown that the infection can be asymptomatic or paucisymptomatic (causing little or no clinical manifestations) in 30–60% of infected individuals, especially in young adults and adults (Plucinski et al., 2021). Asymptomatic individuals were the source for 69% (20–85%) of all infections (Emery et al., 2020). Saliva from asymptomatic individuals contains infectious virus. Surprisingly, the viral load was found to be significantly similar between asymptomatic and symptomatic patients infected with SARS-CoV-2 (p = 0.573). Since the beginning of the pandemic, there has been controversy about the infectivity of asymptomatic patients. With the aforementioned limitation on the robustness of existing studies which are based on considerably smaller data sets, most studies demonstrate more rapid viral clearance in asymptomatic individuals than in symptomatic ones (McEvoy et al., 2021). A large representative sample with longitudinal data has shown that both symptomatic and asymptomatic patients are often characterized by a similar amount of virus at the onset of infection (Lavezzi et al., 2020). It is reported that approximately 40–45% of patients infected with SARS-CoV-2 will remain asymptomatic (Ora and Topol, 2020). Additionally, individuals with mild, non-specific, asymptomatic symptoms are difficult to identify and quarantine (Han et al., 2021). The ambiguity surrounding both asymptomatic and presymptomatic conditions is highlighted. They are described as suggestive, and both inconclusive. Because of the high risk of silent spread by asymptomatic individuals, it is imperative that screening programs include those without symptoms (Ora and Topol, 2020; Almadhi et al., 2021).

Screening from symptoms could prioritize tests and increase diagnostic sensitivity (Lan et al., 2020). However, in our study, salivary load quantification is not discriminated on the number and nature of reported symptoms except for headache. General non-respiratory symptoms (eye pain, muscle pain, general malaise, fever, headache, and extreme fatigue), although not very specific, are the strongest independent predictors of positive tests (Tostmann et al., 2020). As a non-specific symptom, headache can occur not only in COVID-19 but also in other viral diseases. Therefore, headache alone may not raise suspicion of SARS-CoV-2 infection although headache was 1.7 times more common in patients with COVID-19 respiratory viral infection than in those with non-COVID-19 respiratory viral infection with p = 0.04 (Correa et al., 2020; Mutiaa, 2021). The presence of gastrointestinal symptoms associated with salivary viral load in COVID-19 patients raises questions about the impact of COVID-19 infection on the quality of life of at-risk subjects. It is quite plausible to observe the development of several gastro-intestinal symptoms induced by SARS-CoV-2 infection in patients, ranging from nausea, vomiting, and diarrhea to loss of appetite and abdominal pain (Yusuf et al., 2021).

Chemosensory dysfunctions, especially hyposmia, anosmia, hygeusia, and ageusia, are one of the major symptoms of SARS-CoV2 infection (Srinivasan, 2021). Self-reported loss of smell and taste is a better prognosticator than other symptoms such as cough, fatigue, or fever for predicting symptomatic infection (Mastrangelo et al., 2021). Our results indicate that SARS-CoV-2 levels in saliva do not correlate with taste alterations.

First limitation of our study is that it focused on the second wave of the epidemic in the second half of 2020. Adaptation of salivary quantification guidelines in relation to newly detected SARS-CoV-2 variants is necessary. At the time of the study the variant circulating in France was predominantly the UK variant (B.1.1.7) and not the Delta variant (B.1.617.2) which is now detected in the majority of cases. Thus, it is likely that the results would be different if the study were conducted now since the delta variant has different characteristics (Mlcochova et al., 2021).
Secondly, we also clearly explained the ambiguity surrounding asymptomatic vs. presymptomatic status. We describe them as suggestive, not conclusive. While measuring viral load can be useful in clinical practice, a positive RT-qPCR result does not necessarily mean that the person is still infectious or still has significant disease. The RNA could be from a non-viable virus and/or the amount of live virus could be too low to allow transmission (Trunfio et al., 2021). Contacts of a carrier with a high viral salivary load may have a higher risk of acquiring infection, but to date there is no evidence that acquired infection will be more likely to be symptomatic or severe (Li R. et al., 2020; Hasanoglu et al., 2021; van Kampen et al., 2021).

Strengths of our study is that, although post hoc studies have revealed the importance of SARS-CoV-2 corona virus 2 transmission from both asymptomatic and mildly symptomatic cases, the virologic basis for their infectivity remains largely unquantified (Jones et al., 2021). Despite PCR method do not measure infectious virus, our study produces original and robust quantitative data applied to an ambulatory adult population susceptible to be the prime actor of transmission until effective vaccines have been distributed widely.

CONCLUSION

Our results raise the possibility that the oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission. This result may have public health implications if enhanced saliva samples are used for asymptomatic screening. Considering oral SARS-CoV-2 infection and the ease of saliva for transmission, it remains critical to further understanding of the dominant modes of viral spread across the spectrum of asymptomatic, pre-symptomatic and symptomatic individuals.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Committee for the Protection of Persons South Mediterranean III, France. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

FC, DB, and CD proposed the original study idea and designed the trial and study protocol. DB and FC contributed to the data interpretation and wrote the first draft of the manuscript. FC, CD, and HP verified the data. EG, AE, ML, and JD were responsible for the site work including the recruitment, follow up and data collection. HP monitored the trial. DB did the main analysis. CD, EG, and JD contributed to the revision of the manuscript. All authors reviewed and accepted the manuscript before submission.

FUNDING

This study was supported by the Curaden AG, Kriens, Switzerland and the Health, Systemic, Process EA 4129 Research Unit, University of Lyon, France. The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

ACKNOWLEDGMENTS

We thank and acknowledge all the patients and trial team members. More particularly, Sophie Lengagne, Eva Geraud and Anthea Loiez from the Emile Roux Hospital Center (Le Puy-en-Velay, France); Louis Gauthier from the Protestant Infirmary (Lyôn, France), Séverine Poupblanc, Anne-Hélène Boivin from the Intercommunal Hospital Center of “Mount de Marsan et du Pays des Sources” (Mont de Marsan, France); Armand Sophie, Caroline Gagneux, Adrien Didelot, Matthieu Pecquet, Marie Paul Perraud Josiane Thimonier (Cadres des services) from Saint Joseph Saint Luc Hospital (Lyôn, France). We also thank all the technician from the CNR for their work. We thank Stéphane Morisset independent statistician and special adviser. We also extend our thanks to Eric Bomel, EZUS, University Lyon1 who provided central administrative support to the project, and Eric Gonzalez Garcia, from Greiner Bio-One GmbH (Kremshuenster, Austria) who provided kindly technical support.

REFERENCES

Abasiyanik, M. F., Flood, B., Lin, J., Ozcan, S., Rouhani, S. J., Pyzer, A., et al. (2021). Sensitive detection and quantification of SARS-CoV-2 in saliva. Sci. Rep. 11:12425. doi: 10.1038/s41598-021-91835-7
Accorsi, E. K., Qiu, X., Rumpler, E., Kennedy-Shaffer, L., Kahn, R., Joshi, K., et al. (2021). How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. Eur. J. Epidemiol. 36, 179–196. doi: 10.1007/s10654-021-00727-7
Almadhi, M. A., Abdulrahman, A., Sharaf, S. A., AlSaad, D., Stevenson, N. I., Atkin, S. L., et al. (2021). The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19. Int. J. Infect. Dis. 105, 656–661. doi: 10.1016/j.ijd.2021.02.100
Alteri, C., Cento, V., Antonello, M., Colagrossi, L., Merli, M., Ughi, N., et al. (2020). Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. PLoS One 15:e0236311. doi: 10.1371/journal.pone.0236311
Bazant, M. Z., and Bush, J. W. M. (2021). A guideline to limit indoor airborne transmission of COVID-19. Proc. Natl. Acad. Sci. U.S.A. 118:e2018995118. doi: 10.1073/pnas.2018995118
Caixeta, D. C., Oliveira, S. W., Cardoso-Sousa, L., Cunha, T. M., Goulart, L. R., Martins, M. M., et al. (2021). One-year update on salivary diagnostic anterior.
of COVID-19. *Front. Public Health* 9:589564. doi: 10.3389/fpubh.2021.589564

Carrouël, F., Valette, M., Perrier, H., Bouscambert-Duchamp, M., Dussart, C., Tramini, P., et al. (2021). Performance of self-collected saliva testing compared with nasopharyngeal swab testing for the detection of SARS-CoV-2. *Viruses* 13:e9895. doi: 10.3390/v130909895

Carrouël, F., Viennot, S., Valette, M., Cohen, J.-M., Dussart, C., and Bourgeois, D. (2020). Salivary and Nasal detection of the SARS-CoV-2 virus after antiviral mouthrinses (BCCovid): a structured summary of a study protocol for a randomised controlled trials. *Trials* 21:906. doi: 10.1186/s13636-020-04846-6

Ceron, J. J., Lamy, E., Martinez-Subiela, S., Lopez-Jornet, P., Capela-Silva, F., Eckersall, P. D., et al. (2020). Use of saliva for diagnosis and monitoring the SARS-CoV-2: a general perspective. *J. Clin. Med.* 9:1491. doi: 10.3390/jcm9051491

Chua, G. T., Wong, J. S. C., To, K. K. W., Lam, I. C. S., Yau, F. Y. S., Chan, W. H., et al. (2021). Saliva viral load better correlates with clinical and immunological profiles in children with coronavirus disease 2019. *Emerg Microbes Infect.* 10, 235–241. doi: 10.1080/22221751.2021.1878937

Correa, A. O., Feitosa, P. W. G., Moreira, J. L., de, S., Nogueira, S. ÁR., Fonseca, R. B., et al. (2020). Neurological manifestations of COVID-19 and other coronaviruses: a systematic review. *Neurol. Psychiatry Brain Res.* 37, 27–32. doi: 10.1016/j.nprb.2020.05.008

Emery, J. C., Russell, T. W., Liu, Y., Hellewell, J., Pearson, C. A., Cmmid Covid-19 Working Group, et al. (2020). The contribution of asymptomatic SARS-CoV-2 infections to transmission on the diamond princess cruise ship. *Elife* e58699. doi: 10.7554/Life.58699

Han, M. S., Byun, J.-H., Cho, Y., and Rim, J. H. (2021). RT-PCR for SARS-CoV-2: quantitative versus qualitative. *Lancet Infect. Dis.* 21:165. doi: 10.1016/S1473-3099(20)30442-2

Hart, W. S., Maini, P. K., and Thompson, R. N. (2021). High infectiousness immediately before COVID-19 symptom onset highlights the importance of continued contact tracing. *Elife* 10:e55534. doi: 10.7554/Ellfe.55534

Hasanoglu, I., Korukluoglu, G., Asilturk, D., Cosgun, Y., Kalem, A. K., Alas, A. B., et al. (2021). Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. *Infection* 49, 117–126. doi: 10.1007/s11573-020-01548-8

Huang, N., Pérez, P., Kato, T., Mikami, Y., Okuda, K., Gilmore, R. C., et al. (2021). Relative infectiousness of asymptomatic SARS-CoV-2 infected persons compared with symptomatic individuals: a rapid scoring review. *BMJ open* 11:e043254. doi: 10.1136/bmjopen-2020-043254

Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., et al. (2021). SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. *Nature* 599, 114–119. doi: 10.1038/s41586-021-03944-y

Moreira, V. M., Mascarenhas, P., Machado, V., Botelho, J., Mendes, J. J., Taveira, N., et al. (2021). Diagnosis of SARS-CoV-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. *Diagnoses* 11:363. doi: 10.3390/diagnostics11020363

Mutiawati, E., Syahrul, S., Fahriani, M., Fajar, J. K., Mamada, S. S., Maliga, H. A., et al. (2021). Global prevalence and pathogenesis of headache in COVID-19: a systematic review and meta-analysis. *F1000Res* 9:1316. doi: 10.12688/f1000research.27334.4

Pang, Y., Zhang, D., Yang, P., Poon, L. L. M., and Wang, Q. (2020). Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect. Dis.* 20, 411–412. doi: 10.1016/S1473-3099(20)30113-4

Plucinsky, M. M., Wallace, M., Uehara, A., Kurbatova, E. V., Tobolowsky, F. A., Schneider, Z. D., et al. (2021). Coronavirus disease 2019 (COVID-19) in Americans aboard the diamond princess cruise ship. *Clin. Infect. Dis.* 72, e448–e457. doi: 10.1093/cid/ciaa180

Qian, J., Zhao, L., Ye, R.-Z., Li, X.-J., and Liu, Y.-L. (2020). Age-dependent gender. *Front. Med.* 11:716563. doi: 10.3389/fcimb.2021.716563

Sakpota, D., Seland, T. M., Galtung, H. K., Sand, L. P., Giannecchi, S., To, K. K. W., et al. (2020). COVID-19 salivary signature: diagnostic and research opportunities. *J. Clin. Pathol.* jclinpath-2020-206834. doi: 10.1136/jclinpath-2020-206834

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., et al. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA* 323, 1582–1589. doi: 10.1001/jama.2020.4783

Srinivasan, M. (2021). Taste dysfunction and long COVID-19. *Front. Cell Infect. Microbiol.* 11:716563. doi: 10.3389/fcimb.2021.716563

To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., et al. (2020). Temporal profiles of viral load in posterior oropharyngeal saliva
samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect. Dis.* 20, 565–574. doi: 10.1016/S1473-3099(20)30196-1

Tostmann, A., Bradley, J., Bousmina, T., Yiek, W.-K., Holwerda, M., Bleeker-Rovers, C., et al. (2020). Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. *Euro Surveill* 25:2000508. doi: 10.2807/1560-7917.ES.2020.25.16.2000508

Trunfio, M., Longo, B. M., Alladio, F., Venuti, F., Cerutti, F., Ghisetti, V., et al. (2021). On the SARS-CoV-2 "variolation hypothesis": no association between viral load of index cases and COVID-19 severity of secondary cases. *Front. Microbiol.* 12:646679. doi: 10.3389/fmicb.2021.646679

van Kampen, J. J. A., van de Vijver, D. A. M. C., Fraaij, P. L. A., Haagmans, B. L., Lamers, M. M., Okba, N., et al. (2021). Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat. Commun.* 12:267. doi: 10.1038/s41467-020-20568-4

Vasudevan, H. N., Xu, P., Servellita, V., Miller, S., Liu, L., Gopez, A., et al. (2021). Digital droplet PCR accurately quantifies SARS-CoV-2 viral load from crude lysate without nucleic acid purification. *Sci. Rep.* 11:780. doi: 10.1038/s41598-020-80715-1

Walsh, K. A., Jordan, K., Clyne, B., Rohde, D., Drummond, L., Byrne, P., et al. (2020). SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *J. Infect.* 81, 357–371. doi: 10.1016/j.jinf.2020.06.067

Yoon, J. G., Yoon, J., Song, J. Y., Yoon, S. Y., Lim, C. S., Seong, H., et al. (2020). Clinical significance of a high SARS-CoV-2 viral load in the saliva. *J. Korean Med. Sci.* 35:e195. doi: 10.3346/jkms.2020.35.e195

Yu, F., Yan, L., Wang, N., Yang, S., Wang, L., Tang, Y., et al. (2020). Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. *Clin. Infect. Dis.* 71, 793–798. doi: 10.1093/cid/ciaa345

Yusuf, F., Fahriani, M., Mamada, S. S., Frediansyah, A., Abubakar, A., Maghfurah, D., et al. (2021). Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: a systematic review and meta-analysis. *F1000Res* 10:301. doi: 10.12688/f1000research.52216.1

Zheng, S., Fan, J., Yu, F., Feng, B., Lou, B., Zou, Q., et al. (2020). Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* 369:m1443. doi: 10.1136/bmj.m1443

Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., et al. (2020). SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N. Engl. J. Med.* 382, 1177–1179. doi: 10.1056/NEJMc2001737

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Carrouel, Gadea, Esparcieux, Dimet, Langlois, Dussart and Bourgeois. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.